Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Completed1

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

completed133%

active_not_recruiting133%

not_yet_recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_2

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

NCT06775041

not_yet_recruitingphase_2

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

NCT05847179

completedphase_1

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963

Clinical Trials (3)

Showing 3 of 3 trials

NCT06775041Phase 2

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

Active Not Recruiting

NCT05847179Phase 2

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

Not Yet Recruiting

NCT04512963Phase 1

Phase I Study of Progerinin in Healthy Volunteers

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3